Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 16/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 2/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10097524 | 0.93 | EPHX2 (0.52) | EPHX2AURKAAURKBKDR | |
| SCHEMBL10097512 | 0.92 | EPHX2 (0.48) | EPHX2AURKAAURKBKDR | |
| SCHEMBL10097510 | 0.92 | EPHX2 (0.49) | EPHX2AURKAAURKBKDR | |
| SCHEMBL10097697 | 0.92 | EPHX2 (0.53) | EPHX2 | |
| SCHEMBL10097527 | 0.90 | EPHX2 (0.48) | EPHX2KDR | |
| SCHEMBL10097478 | 0.89 | EPHX2 (0.47) | EPHX2MAPK1AURKAAURKBKDR | |
| SCHEMBL10097487 | 0.89 | POLB (0.48) | EPHX2KDR | |
| SCHEMBL10096408 | 0.88 | EPHX2 (0.49) | EPHX2MAPK1PIK3CAMAPK8MAPK9 | |
| SCHEMBL10097633 | 0.88 | EPHX2 (0.47) | EPHX2KDR | |
| SCHEMBL10097551 | 0.88 | EPHX2 (0.46) | EPHX2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | PTC THERAPEUTICS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-7973069-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-7868037-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2010118009-A1 | HCV INHIBITOR AND THERAPEUTIC AGENT COMBINATIONS | PTC THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-7781478-B2 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20070299069-A1 | Methods for treating hepatitis C | PTC THERAPEUTICS, INC. | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110268698-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, LIPC, HCCS | EPHX2 745/4885MAPK1 4616/4885PIK3CA 2171/4885 |
| US-20100292187-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | EPHX2 2630/4885MAPK1 4248/4885PIK3CA 3705/4885 |
| US-20070299069-A1 | Methods for treating hepatitis C | HAVCR2, EIF2AK2, MAVS | EPHX2 2630/4885MAPK1 4248/4885PIK3CA 3705/4885 |
| US-20120027721-A1 | HCV Inhibitor and Therapeutic Agent Combinations | HAVCR2, SERPINB1, ENPEP | EPHX2 2880/4885MAPK1 3869/4885PIK3CA 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.